Ireland Awaits Funding Decision for Rare Genetic Disorder Treatment Drug

The Irish Health Service Executive is expected to announce whether it will fund Skyclarys (omaveloxolone), a recently approved medication for a rare genetic condition. The pending decision impacts patient access to life-changing therapy in Ireland.